Icon

XADAGO (nda207145)- (EQ 50MG BASE,EQ 100MG BASE)

SAFINAMIDE MESYLATE MDD US
EQ 50MG BASE,EQ 100MG BASE
Yes No
2031-Mar-21 2022-Mar-21
None None
None No
XADAGO is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
2 2 0
Total Other Developers 11
Drugs with Suitability No
EQ 50MG BASE ** ** - - -
EQ 100MG BASE ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.